141 related articles for article (PubMed ID: 20514447)
1. Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression.
Malaponte G; Zacchia A; Bevelacqua Y; Marconi A; Perrotta R; Mazzarino MC; Cardile V; Stivala F
Oncol Rep; 2010 Jul; 24(1):81-7. PubMed ID: 20514447
[TBL] [Abstract][Full Text] [Related]
2. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
3. GLI2-mediated melanoma invasion and metastasis.
Alexaki VI; Javelaud D; Van Kempen LC; Mohammad KS; Dennler S; Luciani F; Hoek KS; Juàrez P; Goydos JS; Fournier PJ; Sibon C; Bertolotto C; Verrecchia F; Saule S; Delmas V; Ballotti R; Larue L; Saiag P; Guise TA; Mauviel A
J Natl Cancer Inst; 2010 Aug; 102(15):1148-59. PubMed ID: 20660365
[TBL] [Abstract][Full Text] [Related]
4. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
5. TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
Am J Pathol; 2012 Dec; 181(6):2202-16. PubMed ID: 23063511
[TBL] [Abstract][Full Text] [Related]
6. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinase-2 in patients with malignant melanoma.
Wollina U; Hipler UC; Knöll B; Graefe T; Kaatz M; Kirsch K
J Cancer Res Clin Oncol; 2001 Oct; 127(10):631-5. PubMed ID: 11599800
[TBL] [Abstract][Full Text] [Related]
9. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta.
Iida J; McCarthy JB
Melanoma Res; 2007 Aug; 17(4):205-13. PubMed ID: 17625450
[TBL] [Abstract][Full Text] [Related]
10. A role for plasma transforming growth factor-beta and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?
Ahimastos AA; Aggarwal A; Savarirayan R; Dart AM; Kingwell BA
Atherosclerosis; 2010 Mar; 209(1):211-4. PubMed ID: 19717156
[TBL] [Abstract][Full Text] [Related]
11. Role of TGF-β in melanoma.
Busse A; Keilholz U
Curr Pharm Biotechnol; 2011 Dec; 12(12):2165-75. PubMed ID: 21619542
[TBL] [Abstract][Full Text] [Related]
12. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Laine S
Acta Oncol; 2000; 39(7):877-9. PubMed ID: 11145448
[TBL] [Abstract][Full Text] [Related]
13. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
[TBL] [Abstract][Full Text] [Related]
14. CD147 and matrix-metalloproteinase-2 expression in metastatic and non-metastatic uveal melanomas.
Lüke J; Vukoja V; Brandenbusch T; Nassar K; Rohrbach JM; Grisanti S; Lüke M; Tura A
BMC Ophthalmol; 2016 Jun; 16():74. PubMed ID: 27255356
[TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.
Tas F; Duranyildiz D; Oguz H; Disci R; Kurul S; Yasasever V; Topuz E
Med Oncol; 2005; 22(1):39-44. PubMed ID: 15750195
[TBL] [Abstract][Full Text] [Related]
16. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein.
Ntayi C; Labrousse AL; Debret R; Birembaut P; Bellon G; Antonicelli F; Hornebeck W; Bernard P
J Invest Dermatol; 2004 Feb; 122(2):256-65. PubMed ID: 15009703
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Becker JC; Ruiter DJ; van Muijen GN
J Invest Dermatol; 2000 Oct; 115(4):625-32. PubMed ID: 10998134
[TBL] [Abstract][Full Text] [Related]
18. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.
Altomonte M; Montagner R; Fonsatti E; Colizzi F; Cattarossi I; Brasoveanu LI; Nicotra MR; Cattelan A; Natali PG; Maio M
Br J Cancer; 1996 Nov; 74(10):1586-91. PubMed ID: 8932339
[TBL] [Abstract][Full Text] [Related]
19. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function.
Sarper M; Allen MD; Gomm J; Haywood L; Decock J; Thirkettle S; Ustaoglu A; Sarker SJ; Marshall J; Edwards DR; Jones JL
Breast Cancer Res; 2017 Mar; 19(1):33. PubMed ID: 28330493
[TBL] [Abstract][Full Text] [Related]
20. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
